Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobi, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobi, J
American Journal of Health-System Pharmacy, Vol 59, Issue suppl_1, S3-S8
Copyright © 2002 by American Society of Health-System Pharmacists

Articles

Pathophysiology of sepsis

J Jacobi


The roles of inflammation and coagulation in the pathophysiology of sepsis are described. Sepsis results when an infectious insult triggers a localized inflammatory reaction that then spills over to cause systemic symptoms of fever or hypothermia, tachycardia, tachypnea, and either leukocytosis or leukopenia. These clinical symptoms are called the systemic inflammatory response syndrome. Severe sepsis is defined by dysfunction of one of the major organ systems or unexplained metabolic acidosis. The inflammatory reaction is mediated by the release of cytokines, including tumor necrosis factor-alpha, interleukins, and prostaglandins, from neutrophils and macrophages. The cytokines activate the extrinsic coagulation cascade and inhibit fibrinolysis. These overlapping processes result in microvascular thrombosis; thrombosis is one potential factor producing organ dysfunction. Activation of the coagulation system leads to consumption of endogenous anticoagulants (e.g., protein C and antithrombin); this may be an important factor in the development of microvascular coagulation. Antiinflammatory mediators as well as inflammatory mediators have a role in sepsis, and an excess of either can result in poor patient outcomes. Sepsis is a complex syndrome involving activation of a variety of systems.
 



This article has been cited by other articles:


Home page
 RNAHome page
K. Kajimoto, H. Naraba, and N. Iwai
MicroRNA and 3T3-L1 pre-adipocyte differentiation
RNA, September 1, 2006; 12(9): 1626 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
V. Dombrovskiy, A. Martin, J. Sunderram, and H. Paz
Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals.
Am. J. Health Syst. Pharm., June 15, 2006; 63(12): 1151 - 1156.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Ivanova, G. Salama, R. M. Clancy, N. F. Schor, K. D. Nylander, and D. A. Stoyanovsky
Formation of Nitroxyl and Hydroxyl Radical in Solutions of Sodium Trioxodinitrate: EFFECTS OF pH AND CYTOTOXICITY
J. Biol. Chem., October 31, 2003; 278(44): 42761 - 42768.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society of Health-System Pharmacists.